Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-3201 Injection Receives Drug Clinical Trial Approval Notice
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-3201 Injection, and will soon initiate clinical trials. The applied indication: Alzheimer's disease.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice for SHR-3201 Injection approved and issued by the National Medical Products Administration, and will conduct clinical trials in the near future. The applied indication: Alzheimer's disease.
SHR-3201 Injection is an independently developed drug by the company for the treatment of AD, which can clear disease biomarkers in patients' brains and delay cognitive decline. Upon review, no similar drugs have been approved for marketing domestically or internationally. As of now, the cumulative R&D investment in SHR-3201 Injection-related projects is approximately RMB 48.8 million (unaudited).
Related Articles
BEISEN HOLDING (09669) repurchased 130,600 shares for HK$416,700 on October 13.
YUM CHINA (09987) repurchased 23,800 shares for HK$7.9866 million on October 12.
LIANLIAN (02598) repurchased 187,500 shares on October 13 for HK$601,900.
BEISEN HOLDING (09669) repurchased 130,600 shares for HK$416,700 on October 13.
YUM CHINA (09987) repurchased 23,800 shares for HK$7.9866 million on October 12.
LIANLIAN (02598) repurchased 187,500 shares on October 13 for HK$601,900.
